Dataset: Transcription profiling of human non anaplastic T-cell lymphoma
[u'A \uff91Cartes d\uff92Identite des Tumeurs\uff92 (CIT) project from the french Ligue Nationale Contre le Cancer (', {u'a': {u'href':...
[u'A \uff91Cartes d\uff92Identite des Tumeurs\uff92 (CIT) project from the french Ligue Nationale Contre le Cancer (', {u'a': {u'href': u'http://cit.ligue-cancer.net', u'target': u'_blank', u'$': u'http://cit.ligue-cancer.net'}}, u') | Affymetrix HG-U133 Plus 2.0 : 17 AITL biopsies, 2 AITL sorted cells, 16 PTCL NOS biopsies | The molecular alterations underlying the pathogenesis of angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma, unspecified (PTCL-u) are largely unknown. In order to characterize the ontogeny and molecular differences between both entities, a series of AITLs (n = 18) and PTCLs-u (n = 16) was analyzed using gene expression profiling. Unsupervised clustering correlated with the pathological classification and with CD30 expression in PTCL-u. The molecular profile of AITLs was characterized by a strong microenvironment imprint (overexpression of B-cell- and follicular dendritic cell-related genes, chemokines, and genes related to extracellular matrix and vascular biology), and overexpression of several genes characteristic of normal follicular helper T (T(FH)) cells (CXCL13, BCL6, PDCD1, CD40L, NFATC1). By gene set enrichment analysis, the AITL molecular signature was significantly enriched in published T(FH)-specific genes. The enrichment was higher for sorted AITL cells than for tissue samples. Overexpression of several T(FH) genes was validated by immunohistochemistry in AITLs. A few cases with molecular T(FH)-like features were identified among CD30(-) PTCLs-u. Our findings strongly support that T(FH) cells represent the normal counterpart of AITL, and suggest that the AITL spectrum may be wider than suspected, as a subset of CD30(-) PTCLs-u may derive from or be related to AITL.| Submitter : Aurelien de Reynies
- Species:
- human
- Samples:
- 35
- Source:
- E-TABM-783
- PubMed:
- 17284527
- Updated:
- Dec.12, 2014
- Registered:
- Sep.22, 2014
Sample | Age | DiseaseStage | Age(years) | SampleType | DiseaseState |
---|---|---|---|---|---|
CIT-HS-NATL-PG-S01 | 68 | 4 | tissue | angioimmunoblastic T-cell lymphoma | |
CIT-HS-NATL-PG-S02 | 71 | 3 | tissue | angioimmunoblastic T-cell lymphoma | |
CIT-HS-NATL-PG-S03 | 53 | n/a | tissue | angioimmunoblastic T-cell lymphoma | |
CIT-HS-NATL-PG-S04 | 59 | n/a | tissue | angioimmunoblastic T-cell lymphoma | |
CIT-HS-NATL-PG-S05 | 65 | 4 | tissue | angioimmunoblastic T-cell lymphoma | |
CIT-HS-NATL-PG-S06 | 50 | 4 | tissue | angioimmunoblastic T-cell lymphoma | |
CIT-HS-NATL-PG-S07 | 74 | 4 | tissue | angioimmunoblastic T-cell lymphoma | |
CIT-HS-NATL-PG-S08 | 75 | 4 | tissue | angioimmunoblastic T-cell lymphoma | |
CIT-HS-NATL-PG-S09 | 81 | 4 | tissue | angioimmunoblastic T-cell lymphoma | |
CIT-HS-NATL-PG-S10 | 53 | 4 | tissue | angioimmunoblastic T-cell lymphoma | |
CIT-HS-NATL-PG-S11 | 64 | 4 | tissue | angioimmunoblastic T-cell lymphoma | |
CIT-HS-NATL-PG-S12 | 71 | 4 | tissue | angioimmunoblastic T-cell lymphoma | |
CIT-HS-NATL-PG-S13 | 69 | 3 | tissue | angioimmunoblastic T-cell lymphoma | |
CIT-HS-NATL-PG-S14 | 83 | n/a | tissue | angioimmunoblastic T-cell lymphoma | |
CIT-HS-NATL-PG-S02 | 71 | 3 | tissue | angioimmunoblastic T-cell lymphoma | |
CIT-HS-NATL-PG-S16 | 81 | n/a | tissue | angioimmunoblastic T-cell lymphoma | |
CIT-HS-NATL-PG-S17 | 67 | 4 | tissue | angioimmunoblastic T-cell lymphoma | |
CIT-HS-NATL-PG-S17C | n/a | n/a | sorted cells | angioimmunoblastic T-cell lymphoma | |
CIT-HS-NATL-PG-S18C | 54 | 4 | sorted cells | angioimmunoblastic T-cell lymphoma | |
CIT-HS-NATL-PG-S19 | 21 | 4 | tissue | peripheral T-cell lymphoma, not otherwise specified | |
CIT-HS-NATL-PG-S20 | 69 | 4 | tissue | peripheral T-cell lymphoma, not otherwise specified | |
CIT-HS-NATL-PG-S21 | 45 | 4 | tissue | peripheral T-cell lymphoma, not otherwise specified | |
CIT-HS-NATL-PG-S22 | 77 | 3 | tissue | peripheral T-cell lymphoma, not otherwise specified | |
CIT-HS-NATL-PG-S23 | 59 | 4 | tissue | peripheral T-cell lymphoma, not otherwise specified | |
CIT-HS-NATL-PG-S24 | 69 | 1 | tissue | peripheral T-cell lymphoma, not otherwise specified | |
CIT-HS-NATL-PG-S25 | 63 | 3 | tissue | peripheral T-cell lymphoma, not otherwise specified | |
CIT-HS-NATL-PG-S26 | 32 | 3 | tissue | peripheral T-cell lymphoma, not otherwise specified | |
CIT-HS-NATL-PG-S27 | 56 | 4 | tissue | peripheral T-cell lymphoma, not otherwise specified | |
CIT-HS-NATL-PG-S28 | 62 | 4 | tissue | peripheral T-cell lymphoma, not otherwise specified | |
CIT-HS-NATL-PG-S29 | 57 | 4 | tissue | peripheral T-cell lymphoma, not otherwise specified | |
CIT-HS-NATL-PG-S30 | 66 | 4 | tissue | peripheral T-cell lymphoma, not otherwise specified | |
CIT-HS-NATL-PG-S31 | 35 | 1 | tissue | peripheral T-cell lymphoma, not otherwise specified | |
CIT-HS-NATL-PG-S32 | 67 | 3 | tissue | peripheral T-cell lymphoma, not otherwise specified | |
CIT-HS-NATL-PG-S33 | 42 | 4 | tissue | peripheral T-cell lymphoma, not otherwise specified | |
CIT-HS-NATL-PG-S34 | 54 | 4 | tissue | peripheral T-cell lymphoma, not otherwise specified |